ArticleEpilepsia open2025
Self-limited familial focal epilepsy caused by ANK2 variants: A potentially under-recognized condition.
Article in Epilepsia open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Self-limited familial focal epilepsy caused by ANK2 variants: A potentially under-recognized condition.Epilepsia open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The Ankyrin 2 (ANK2) gene encodes the ankyrin-B protein (ANKB), which is involved in the organization and stability of membrane ion channels, transporters, and receptors in cardiomyocytes and neurons. Variants in ANK2 genes are initially reported in long QT syndrome and autism. Animal models with ANK2 deletion have exhibited seizures and been anecdotally associated with epilepsy in case reports. Hereby, we reported a Taiwanese family with the ANK2 pathogenic variant (chr4:114276707, c.6933del, p.T2312Lfs*2) that affects the giant ankyrin-B isoform. The family members presented with young-onset self-limited focal epilepsy, and achieved seizure-free in adulthood with antiseizure medications. Interestingly, the electrocardiogram revealed no obvious cardiac phenotype. We further reviewed reported ANK2-related epilepsies. Most variants are de novo and loss-of-function variants. Most patients had young epilepsy or neonatal seizures. Notably, most cases of ANK2-related epilepsy are self-limited and pharmaco-responsive, which suggests that it is likely to be underdiagnosed. With the increased availability of whole exome sequencing, the diagnosis of ANK2-related epilepsies may increase. The co-existence of QT prolongation on electrocardiogram, autism, and a positive family history of cardiac arrhythmia or sudden death may provide important clues in the clinical diagnosis of ANK2-related epilepsy. Furthermore, a correct genetic diagnosis of ANK2-related epilepsy will initiate close cardiac surveillance to avoid the potential sudden death risk of this disorder. PLAIN LANGUAGE SUMMARY: ANK2 has long been regarded as an arrhythmic gene. This study reported the first familial ANK2-related epilepsy, highlighting the role of ANK2 in epileptogenesis. Most reported ANK2-related epilepsies are self-limited and pharmaco-responsive, suggesting that they are likely to be underdiagnosed. Literature review of the phenotype and genotype of ANK2 showed that LOF ANK2 variants tend to have CNS phenotypes, whereas missense variants are arrhythmic. Early detection of ANK2 variants in epilepsy patients is worthwhile considering the potential sudden death risk of this disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.